bausch health companies inc. (nyse/tsx: bhc) is a global company that develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. we are delivering on our commitments as we build an innovative company dedicated to advancing global health. our approximately 22,000 employees are united around our mission of improving people’s lives with our health care products, and we manufacture and market health care products directly or indirectly in approximately 100 countries.five pillars, or guiding principles, represent the foundation on which we are realizing our mission as an organization: people, quality health care outcomes, customer focus, innovation and efficiency. more information can be found at www.bauschhealth.com.###
Company profile
Ticker
BHC
Exchange
Website
CEO
Thomas J. Appio
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BIOVAIL Corp, BIOVAIL CORP INTERNATIONAL, BIOVAIL CORPORATION INTERNATIONAL, Valeant Pharmaceuticals International, Inc.
SEC CIK
Corporate docs
Subsidiaries
Bausch & Lomb Argentina S.R.L. • Waicon Vision S.A. • AcuFocus Australia • Bausch Health Australia Pty Limited • Bausch & Lomb (Australia) Pty Limited • Bausch & Lomb Australia Holdings Pty Limited • Solta Medical Australia Pty Limited • BAUSCH HEALTH LLC • Bausch & Lomb Pharma S.A. • PharmaSwiss BH Društvo za trgovinu na veliko d.o.o. ...
BHC stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
22 Feb 24
8-K
Bausch Health Announces Fourth-quarter and Full-year 2023 Results
22 Feb 24
8-K
Bausch Health Announces Board Refreshment
1 Feb 24
8-K/A
Financial Statements and Exhibits
13 Nov 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Bausch Health Announces Third-quarter 2023 Results
2 Nov 23
8-K
Bausch Health’s Bausch + Lomb Announces About Bausch Health
29 Sep 23
8-K/A
Departure of Directors or Certain Officers
29 Sep 23
8-K
Bausch Health Announces Cfo Transition Plan
18 Sep 23
8-K
Other Events
14 Sep 23
Transcripts
BHC
Earnings call transcript
2023 Q3
2 Nov 23
BHC
Earnings call transcript
2023 Q2
3 Aug 23
BHC
Earnings call transcript
2023 Q2
3 Aug 23
BHC
Earnings call transcript
2023 Q1
4 May 23
BHC
Earnings call transcript
2023 Q1
4 May 23
BHC
Earnings call transcript
2022 Q4
23 Feb 23
BHC
Earnings call transcript
2022 Q4
23 Feb 23
BHC
Earnings call transcript
2022 Q3
3 Nov 22
BHC
Earnings call transcript
2022 Q2
9 Aug 22
BHC
Earnings call transcript
2022 Q2
9 Aug 22
Latest ownership filings
4
John S Barresi
4 Mar 24
4
THOMAS APPIO
4 Mar 24
4
Seana Carson
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
SC 13G/A
GOLDENTREE ASSET MANAGEMENT LP
13 Feb 24
SC 13D/A
ICAHN CARL C
7 Feb 24
4
RUSSEL C ROBERTSON
2 Jan 24
4
BRETT ICAHN
2 Jan 24
4
John Paulson
2 Jan 24
4
AMY B WECHSLER
2 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 780.00 mm | 780.00 mm | 780.00 mm | 780.00 mm | 780.00 mm | 780.00 mm |
Cash burn (monthly) | (no burn) | (no burn) | 108.67 mm | 8.00 mm | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | 650.47 mm | 47.89 mm | n/a | n/a |
Cash remaining | n/a | n/a | 129.53 mm | 732.11 mm | n/a | n/a |
Runway (months of cash) | n/a | n/a | 1.2 | 91.5 | n/a | n/a |
Institutional ownership, Q3 2023
81.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 223 |
Opened positions | 35 |
Closed positions | 41 |
Increased positions | 44 |
Reduced positions | 66 |
13F shares | Current |
---|---|
Total value | 2.29 tn |
Total shares | 292.79 mm |
Total puts | 20.81 mm |
Total calls | 11.56 mm |
Total put/call ratio | 1.8 |
Largest owners | Shares | Value |
---|---|---|
Icahn Carl C Et Al | 34.72 mm | $285.42 bn |
Paulson & Co. | 26.44 mm | $217.33 bn |
Goldentree Asset Management | 23.99 mm | $197.18 bn |
NMR Nomura | 18.09 mm | $148.67 bn |
BEN Franklin Resources | 15.80 mm | $129.89 bn |
National Bank of Canada | 15.66 mm | $127.49 bn |
VA Partners I | 14.43 mm | $135.65 mm |
Hudson Bay Capital Management | 11.50 mm | $94.53 bn |
Vanguard | 11.49 mm | $94.43 bn |
BMO Bank of Montreal | 10.87 mm | $94.00 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Mar 24 | Seana Carson | Common Shares, No Par Value | Sell | Dispose S | No | Yes | 9.8 | 133 | 1.30 k | 499,905 |
4 Mar 24 | Seana Carson | Common Shares, No Par Value | Sell | Dispose S | No | Yes | 9.8 | 1,561 | 15.30 k | 500,038 |
4 Mar 24 | Seana Carson | Common Shares, No Par Value | Sell | Dispose S | No | Yes | 9.8 | 199 | 1.95 k | 501,599 |
4 Mar 24 | Seana Carson | Common Shares, No Par Value | Sell | Dispose S | No | Yes | 9.8 | 4,420 | 43.32 k | 501,798 |
1 Mar 24 | Seana Carson | Common Shares, No Par Value | Payment of exercise | Dispose F | No | No | 9.89 | 511 | 5.05 k | 506,218 |
1 Mar 24 | Seana Carson | Common Shares, No Par Value | Payment of exercise | Dispose F | No | No | 9.89 | 16,973 | 167.86 k | 506,729 |
1 Mar 24 | Seana Carson | Common Shares, No Par Value | Payment of exercise | Dispose F | No | No | 9.89 | 5,994 | 59.28 k | 523,702 |
1 Mar 24 | Seana Carson | Common Shares, No Par Value | Payment of exercise | Dispose F | No | No | 9.89 | 765 | 7.57 k | 529,696 |
1 Mar 24 | Thomas Appio | Common Shares, No Par Value | Payment of exercise | Dispose F | No | No | 9.89 | 87,803 | 868.37 k | 1,369,356 |
1 Mar 24 | Thomas Appio | Common Shares, No Par Value | Payment of exercise | Dispose F | No | No | 9.89 | 23,871 | 236.08 k | 1,457,159 |
News
RBC Capital Maintains Sector Perform Rating for Bausch Health Companies: Here's What You Need To Know
23 Feb 24
RBC Capital Maintains Sector Perform on Bausch Health Companies, Raises Price Target to $9
23 Feb 24
Bausch Health Companies Q4 Sales $2.41B Beat $2.30B Estimate, Adjusted Net Income Of $406M
22 Feb 24
Earnings Scheduled For February 22, 2024
22 Feb 24
Preview: Bausch Health Companies's Earnings
21 Feb 24
Press releases
Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma
6 Mar 24
New Survey Finds More Than Half of Past U.S. Colonoscopy Patients Wish They Had Known More Information About Colonoscopies Including Prep Medication Options and How To Prepare for the Procedure
5 Mar 24
Bausch Health Companies to Present at Cowen Annual Health Care Conference
1 Mar 24
Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results
22 Feb 24
Bausch Health Announces Board Refreshment
1 Feb 24